The US Food and Drug Administration is reviewing Nirsevimab, the first-of-its-kind antibody to offer some protection against RSV for all infants in their first year of life.
Mandatory Credit: Shutterstock
Stories this photo appears in:
FDA to review preventative option for RSV in infants, developers say
The US Food and Drug Administration has accepted a biologics license application for a long-acting antibody for the prevention of lower respiratory tract infections caused by the respiratory syncytial virus, according to the developers of the antibody. If approved, it could be available for use in some infants and toddlers later this year.
